(A.k.a. HMG-CoA reductase inhibitors). Convincing cases reports of ILD contrast with the lack of epidemiological evidence (PMID 17223772, 23299962). Cerivastatin was recalled/discontinued worldwide in 2001, due to rhabdomyolysis, a complication common to statins and some other lipid-lowering agents. A paper in 2024 from one center (PMID 38460070) blamed statins at the origin of 455 fibrotic ILD cases…
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)
Pneumonitis (interstitial lung disease/ILD)
Organizing pneumonia pattern (an area or areas of consolidation on imaging)
Acute fibrinous organizing pneumonia (AFOP)
Pulmonary fibrosis
Relapsing or migrating pneumonitis/pneumonia (see also Id)
Pleuroparenchymal fibroelastosis (PPFE)
Interstitial Pneumonitis with Autoimmune Features (IPAF)
The association of ILD and myositis
Path: Organizing pneumonia (OP/BOOP) pattern (see also Id)
Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also pattern If)
Path: NSIP-fibrotic pattern
Path: Endogenous lipoid pneumonia (phospholipidosis)
Path: Pleuroparenchymal fibrosis/fibroelastosis (PPFE)
Path: Foamy inclusions in alveolar macrophages and/or in other lung cells
